Akums Q1 FY25 revenue up 5.1%
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
Subscribe To Our Newsletter & Stay Updated